Trial Profile
A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Acronyms EXTEND
- Sponsors Vertex Pharmaceuticals
- 07 Nov 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 19 Dec 2022 This trial has been completed in France, according to European Clinical Trials Database record.